Background: While there is accumulating evidence that use of nonsteroidal anti-inflammatory drugs (NSAID) decreases breast cancer risk, little is known about the impact of NSAIDs on survival after breast cancer diagnosis.
Introduction
Identification of potential factors affecting breast cancer survival is of great public health importance, as approximately 2.6 million women previously diagnosed with breast cancer are alive in the United States today (1) . Relatively consistent evidence suggests that nonsteroidal anti-inflammatory drugs (NSAID) reduce breast cancer risk (2) . Emerging evidence suggests that NSAIDs might influence cancer prognosis by inducing apoptosis and inhibiting angiogenesis (3) . In the present study, we assessed associations of breast cancer survival with NSAID use in the period prior to breast cancer diagnosis and for aspirin use throughout the lifetime up to the time of diagnosis.
Materials and Methods
A total of 1,024 women with incident, primary, histologically confirmed, invasive breast cancer were identified as part of the Western New York Exposures and Breast Cancer (WEB) study, a population-based casecontrol study conducted between 1996 and 2001 in Western New York, as described in Brasky and colleagues (4) .
Information on demographics, medication use, and breast cancer risk factors was collected through inperson interviews and self-administered questionnaires. Included were questions about the use of aspirin, ibuprofen, and the analgesic acetaminophen in the 12 to 24 months prior to interview. Cox proportional hazards regression models, adjusted for age at diagnosis, race, education, body mass index (kg/m 2 ), menopausal status, stage of breast cancer at diagnosis, estrogen receptor/progesterone receptor status, and use of other NSAIDs, were used to estimate HRs and 95% confidence intervals (95% CI) for all-cause and breast cancer-specific mortality.
The proportional hazards assumption was tested and found to hold in all analyses. All statistical tests were two-sided and considered statistically significant at P < 0.05.
Results
Descriptive characteristics of participants at the time of questionnaire completion are shown in Table 1 . Up to censoring date, 160 deaths occurred with a mean survival time of 7.32 AE 1.74 years. The most frequent cause of death was breast cancer (n ¼ 95), followed by cardiovascular disease (n ¼ 22) and other cancers (n ¼ 11).
Associations between NSAID use and overall and breast cancer survival are shown in Table 2 . Recent use of ibuprofen was associated with reduced all-cause mortality in univariate analysis (HR, 0.65; 95% CI, 0.48-0.89) and borderline significance after adjustment for potential confounders (HR, 0.71; 95% CI, 0.50-1.00). None of the NSAIDs was associated with a reduction in breast cancer mortality (Table 2) . Increasing frequency or intensity of use were also not associated with mortality when stratified by menopausal status (data not shown).
Discussion
Epidemiologic evidence about NSAID use and breast cancer survival is inconsistent. Most studies have focused on postdiagnostic use. In the Iowa Women's Health Study, ever use of any NSAID after diagnosis was associated with a statistically significant reduction in all-cause mortality and a nonsignificant reduction for breast cancer mortality among 591 postmenopausal women with invasive breast cancer (5). Data from the Nurses' Health Study suggested a reduced risk of breast cancer mortality and all-cause mortality for women reporting aspirin use after breast cancer (6) . In contrast, postdiagnosis NSAID use was not associated with allcause or breast cancer mortality in 3,058 breast cancer cases in Wisconsin (7).
Our study was limited to an examination of prediagnostic NSAID use. However, examination of the association of prediagnosis NSAID use and survival after breast cancer diagnosis is also of importance due to the uncertainty about the appropriate timing of NSAIDs use to improve cancer survival (8) . Information on both pre-and postdiagnostic NSAID use is needed to address whether there is a window of time when use is effective, if at all. Another limitation of this study is potential misclassification due to dependence on self-report to assess NSAID use. However, error in report would not be correlated with outcome in that the assessment was done prospectively. In addition, we did not have information on postdiagnosis treatment.
In conclusion, our findings do not support an association between prediagnostic NSAID use and breast cancerspecific mortality or all-cause mortality.
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